Skip to main content
PMC home page
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1961 Oct 28;85(18):974–986.

Clinical Experience with Cyclophosphamide in Malignant Disease *

D A L Dick, A F Phillips
PMCID: PMC1848487  PMID: 13886168

Full text

PDF
975

Images in this article

981Fig. 1a
on p.981
981Fig. 1b
on p.981

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARONOVITCH M., MEAKINS J. F., GROSZMAN M. Use of cyclophosphamide in advanced malignancies. Can Med Assoc J. 1960 Nov 5;83:997–1002. [PMC free article] [PubMed] [Google Scholar]
  2. BERGSAGEL D. E., LEVIN W. C. A prelusive clinical trial of cyclophosphamide. Cancer Chemother Rep. 1960 Jul;8:120–134. [PubMed] [Google Scholar]
  3. BRICHTA G., KUHBOCK J., REIMER E. E. Klinische Erfahrungen mit N-Lost-Phosphamidestern bei Haemopathien. Wien Z Inn Med. 1958 Jul;39(7):306–311. [PubMed] [Google Scholar]
  4. COGGINS P. R., RAVDIN R. G., EISMAN S. H. Clinical evaluation of a new alkylating agent: cytoxan (cyclophosphamide). Cancer. 1960 Nov-Dec;13:1254–1260. doi: 10.1002/1097-0142(196011/12)13:6<1254::aid-cncr2820130614>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  5. DI PIETRO S. [On the antineoplastic action of a cyclic phosphamide ester of nitrogen mustard (endoxan, or B 518). Clinical tests]. Minerva Med. 1959 Oct 27;50:3450–3454. [PubMed] [Google Scholar]
  6. EUFINGER H. [Hormonal regulation in the climacteric and predisposition to carcinoma]. Strahlentherapie. 1959 Dec;110:572–581. [PubMed] [Google Scholar]
  7. FERNBACH D. J., SUTOW W. W., THURMAN W. G., VIETTI T. J. Preliminary report: clinical trials with cyclophosphamide in children with acute leukemia. Cancer Chemother Rep. 1960 Jul;8:102–105. [PubMed] [Google Scholar]
  8. FOYE L. V., Jr, CHAPMAN C. G., WILLETT F. M., ADAMS W. S. Cyclophosphamide. A preliminary study of a new alkylating agent. Arch Intern Med. 1960 Sep;106:365–367. doi: 10.1001/archinte.1960.03820030053009. [DOI] [PubMed] [Google Scholar]
  9. GROSS R. [Clinical experiences with new nitrogen mustard phosphoramide esters in reticuloses and carcinomas]. Acta Unio Int Contra Cancrum. 1960;16:855–859. [PubMed] [Google Scholar]
  10. HAAS E. [Chemotherapeutic prevention of recurrence in surgery in cancer of the ENT area]. Z Laryngol Rhinol Otol. 1960 Jan;39:22–30. [PubMed] [Google Scholar]
  11. KOCH J. [On the therapy of retothel sarcoma]. Z Laryngol Rhinol Otol. 1960 May;39:297–300. [PubMed] [Google Scholar]
  12. KUEHBOECK J., REIMER E. E., STOIBER T. [Peroral palliative therapy of malignant hemoblastoses with an N-Lost phosphamide ester]. Krebsarzt. 1960 Feb;15:49–55. [PubMed] [Google Scholar]
  13. MATTHIAS J. Q., MISIEWICZ J. J., SCOTT R. B. Cyclophosphamide in Hodgkin's disease and related disorders. Br Med J. 1960 Dec 24;2(5216):1837–1840. doi: 10.1136/bmj.2.5216.1837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. PAPAC R., PETRAKIS N. L., AMINI F., WOOD D. A. Comparative clinical evaluation of two alkylating agents: mannitol mustard and cyclophosphamide (cytoxan). J Am Med Assoc. 1960 Mar 26;172:1387–1391. doi: 10.1001/jama.1960.63020130004012. [DOI] [PubMed] [Google Scholar]
  15. SHNIDER B. I. Preliminary studies with cyclophosphamide. Cancer Chemother Rep. 1960 Jul;8:106–111. [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES